Looking to expand your partner network with leading companies like Immutep? Consider joining Inpart's global network for free.
Interview 29 Nov 2022
LAG-3: The next big checkpoint inhibitor target
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […]
